

Safety and efficacy of 4-terpineol against microorganisms associated with blepharitis and common ocular diseases

Chen-Wei Su,¹ Sean Tighe,^{1,2} Hosam Sheha,^{1,2} Anny M S Cheng,² Scheffer C G Tseng¹

To cite: Su C-W, Tighe S, Sheha H, *et al.* Safety and efficacy of 4-terpineol against microorganisms associated with blepharitis and common ocular diseases. *BMJ Open Ophthalmology* 2018;**3**:e000094. doi:10.1136/bmjophth-2017-000094

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjophth-2017-000094>).

Received 2 June 2017
Revised 18 April 2018
Accepted 24 April 2018

ABSTRACT

Objective Microbial infection has been reported to cause blepharitis, conjunctivitis and keratitis. We evaluated the safety and efficacy of a foam formulation of 2% 4-terpineol (T4O) against common ocular microorganisms.

Material and methods The antimicrobial effect of a 2% T4O formulation was evaluated by the United States Pharmacopeia 51 (USP <51>) antimicrobial effectiveness test for 14 and 28 days, as well as by a Time Kill Study (ASTM E2315) with a 60 s exposure time. Its potential of causing skin and ocular irritation was evaluated by the Repeated Insult Patch Test and the Hen's Egg Chorioallantoic Membrane Test, respectively.

Results and discussion It was seen that 2% T4O formulation did not cause ocular irritation, skin irritation, sensitisation or allergic contact dermatitis in human subjects. Most importantly, it killed microorganisms listed in USP <51> at both 14 and 28 days and exerted a rapid killing effect within 60 s against 13 bacteria, 1 fungus and *Acanthamoeba castellanii*.

Conclusion The above finding suggests that 2% T4O formulation is safe and effective in killing microorganisms related to common ocular and skin infective diseases.

Translational relevance Although the clinical efficacy in treating ocular disease was not directly studied; this foam formulation containing 2% T4O, based on the in vitro results of this work, demonstrated that it can potentially be used as a preservative-free cleansing agent for ocular hygiene maintenance due to its ability to exert a broad-spectrum antimicrobial effect without causing ocular or skin irritation.

INTRODUCTION

The eye is continuously exposed to the external environment and is therefore highly susceptible to a multitude of pathogens. The eyelid margin is a particularly favourable environment for the colonisation of pathogens due to the protection of eyelashes and associated adnexal glands. Overproliferation of pathogens in this locale can cause two of the most common eye diseases, that is, blepharitis and meibomitis of the eyelids, which are prevalent eye diseases that constitute at least 37% and 47% of patients seen in clinical practices of ophthalmologists and optometrists, respectively,¹ and are commonly associated with

Key messages

- Many studies have previously suggested a possible role for the topical application of tea tree oil (TTO) as an antiseptic; however, despite years of use, irritation remains as an issue when TTO is applied to human skin. As we recently demonstrated that 4-terpineol (T4O), the major component of TTO is effective in killing *Demodex Mite*; we expanded the study and demonstrated that:
 - The formulation of 2% T4O is safe. It does not cause ocular irritation, skin irritation, sensitisation, or allergic contact dermatitis
 - The formulation of 2% T4O is effective in rapidly killing microorganisms associated with ocular diseases. Particularly, it can also kill *Acanthamoeba castellanii* which is responsible for difficult to treat cases of infectious keratitis.
- Based on the results of this work, we demonstrated that T4O at low concentration can potentially be used in a formulation for ocular hygiene maintenance due to its ability to exert a broad-spectrum antimicrobial effect without causing ocular or skin irritation.

Staphylococcus aureus, *Propionibacterium acnes*, *Candida spp*, *Penicillium spp* and *Moraxella catarrhalis*.²⁻⁴ In fact, these microorganisms are isolated in approximately 50% of the swabs taken from the conjunctiva and tears, and >50% from the eyelids.⁵ In addition, fungi and *Demodex* mites are also found respectively in 79% and 42% of patients with blepharitis.⁴ Due to their prominence, these microorganisms and pathogens may also invade the ocular surface to cause conjunctivitis, keratitis, and even sight-threatening endophthalmitis.^{6,7}

Topical antibiotics or steroids may be used to address the aforementioned diseases; however, these methods may facilitate biofilm formation as well as lead to the emergence of resistant bacterial strains. In addition, the long-term use of topical steroids has been associated with the risk of elevated intraocular pressures and cataract formation.⁸ Due to these short comings, ocular hygiene of



¹Tissue Tech, Inc. R&D Dept. and Ocular Surface Center, Miami, Florida, USA

²Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA

Correspondence to

Dr. Scheffer C G Tseng; stseng@ocularsurface.com

the eyelids is another preferred measure for reducing microbial colonisation.⁹ In this regard, an ocular hygiene agent containing 4-terpineol (T4O), a major component purified from a naturally occurring essential oil of tea tree oil, can be an attractive option since it has been shown to be effective at concentrations between 0.125% and 8% against various microorganisms responsible for infections, such as *S. aureus*, *Pseudomonas aeruginosa* and coagulase-negative staphylococci (CoNS).^{10,11} Moreover, T4O has also been shown to exert an anti-fungal effect against fungi such as *Candida spp*, *Saccharomyces cerevisiae*, *Trichophyton rubrum* and *Penicillium spp* at concentrations of 0.125% to 0.5%.^{11–13} Recently, we have also reported that T4O at a concentration as low as 1% is effective in exerting a miticidal effect against *Demodex* mites,¹⁴ which play a role in blepharitis,^{15–17} unexplained keratitis, superficial corneal vascularisation,¹⁸ marginal infiltration, phlyctenule-like lesions, nodular scarring¹⁹ and rosacea.^{20–22} In addition to its antimicrobial properties, T4O also possesses anti-inflammatory properties by suppressing superoxide production and proinflammatory cytokines.²³ This overwhelming therapeutic potential prompted us to develop a formulation of 2% T4O for ocular hygiene and evaluate its safety and efficacy.

MATERIAL AND METHODS

Preparation of 2% T4O formulation

T4O was obtained from Takasago (CAS: 562-74-3) and contract-prepared by Formulated Solutions (Largo, Florida, USA) to a final concentration of 2% as a foam formulation and stored in a 35×95 mm closed aerosol canister (CCL Container, Hermitage, Pennsylvania, USA) by adding the following excipients: 90.8% water, 2% cocamidopropyl betaine (Glenn Corporation, Lake Elmo, Minnesota, USA), 2% glycerin, 1% caprylic/capric triglyceride, 1% butylene glycol, 0.2% allantoin, 0.75% polysorbate 20 and 0.25% sorbitan oleate (all from Univar USA, Redmond, Washington, USA).

USP <51> antimicrobial effectiveness test

The antimicrobial efficacy of 2% T4O and a control with no T4O (blank) were evaluated against microorganisms listed in Chapter 51 of the United States Pharmacopeia²⁴ (USP <51>) by Alcami Corporation (Wilmington, North Carolina, USA). The control and 2% T4O formulation were separately evaluated following the same procedures/techniques. Briefly, five standard microorganisms, that is, *Escherichia coli* (ATCC 8739), *P. aeruginosa* (ATCC 9027), *S. aureus* (ATCC 6538), *Candida albicans* (ATCC 10231) and *Aspergillus brasiliensis* (ATCC 16404), were inoculated separately and grown at 30°C–35°C on Soybean-Casein Digest Agar, while yeast and mould were grown at 20°C–25°C on Sabouraud Dextrose Agar. On culturing completion, the above-mentioned microorganisms were then added to 0.5%–1% of the volume of 2% T4O at respective concentrations of 3.7×10⁵, 2.3×10⁵, 1.4×10⁵, 4.1×10⁵ and 3.9×10⁵ CFU/mL (colony-forming unit/microlitre). Subsequently, microorganism reduction was

evaluated at days 14 and 28 by calculating the log 2.0 reduction rate. Acceptance for bacterial species is based on a not <2.0 log reduction at 14 days compared with baseline, and no increase observed from 14 to 28 days. For yeast and moulds, the acceptance criteria are based on no increase at 14 and 28 days compared with baseline.

Rapid time kill study

The time kill study was conducted via ASTM E2315 standards^{25,26} by Accugen Laboratories (Willowbrook, Illinois, USA) against various microorganisms. Beforehand, purity of all microorganisms was assured by confirming microorganisms' characteristics by Gram stain²⁷ and colony morphology.²⁸ Microorganisms were then incubated at 35°C–37°C aerobically with 5% CO₂ for aerobic bacteria, at 35°C–37°C under anaerobic conditions for anaerobic bacteria, and at 25°C–28°C for yeast and mould. Appropriate agar, sterile deionised water and phosphate buffer were used to support the growth of each microorganism. Once the microbial population reached at least 10⁶ CFU/mL, 0.5 mL of the inoculum suspension was added to 10 mL of 2% T4O or 10 mL of sterile phosphate buffer as the control. Tubes were then vortexed thoroughly to mix the organisms and placed at ambient temperature (21°C) for 60 s. The inoculum suspensions were enumerated by using pour plate method and colonies were counted to calculate the concentration of viable cells. We then transformed the measured initial and final populations, inoculum suspension and test recoveries to log₁₀ reduction scale as such: Log₁₀ reduction (LR)=mean log₁₀ (microbial population) – mean log₁₀ (surviving test population). Percent reduction (%)=100×(1 – 10 – LR). Surviving organisms were identified by gram stain.

Repeated Insult Patch Test (RIPT) for skin irritation

RIPT was conducted in accordance with the intent and purpose of Good Clinical Practice described in Title 212 of the US Code of Federal Regulations by Essex Testing Clinic (Verona, New Jersey). Following obtaining the informed consent from 58 subjects, the procedure was carried out in two stages. The first stage was the induction phase, in which a 4 cm² square of cotton fabric patch moistened by 0.2 mL of 2% T4O was applied to the back of each subject between the scapulae and the waist for 24 hours. This application was repeated every Monday, Wednesday and Friday until a total of 9 applications was completed. The site was scored prior to the next patch application. On completion of the induction phase, with a rest period of 2 weeks without any applications, the second stage, that is, the challenge phase was conducted by applying the same patch to a previously unpatched test site for 24 and 72 hours. All subjects were instructed to report any delayed skin reactivity that occurred after the final challenge path reading. Dermal responses for both the induction and challenge phases of the study were scored according to the following 6-point scale²⁹: 0=no evidence of any

effect, +=barely perceptible (minimal, faint, uniform or spotty erythema), 1=mild (pink, uniform erythema covering most of the contact site), 2=moderate (pink-red erythema uniform in the entire contact site), 3=marked (bright red erythema with/without petechiae or papules) and 4=severe (deep red erythema with/without vesiculation or weeping).

Hen's Egg Chorioallantoic Membrane test for acute ocular irritation

The ocular irritation evaluation was performed by MB Research Laboratories (Spinnerstown, Pennsylvania, USA) per Protocol No. 47: Hen's Egg Test Chorioallantoic Membrane (HET-CAM) test (Invitox 1992) recommended by ICCVAM³⁰ as an alternative to the Draize eye irritation evaluation in rabbits.³¹⁻³⁴ In this test, 0.9% saline (Hospira, Lake Forest, Illinois, USA) was used as vehicle control and two positive controls were selected per the aforementioned Het-CAM protocol: 0.1 n NaOH and 1% (W/V) sodium dodecyl sulfate (SDS, Fisher, Waltham, Maryland, USA) in distilled water. The test substance was prepared by adding 1 mL 2% T4O with 9 mL of 0.9% saline. Hen eggs were incubated at 32–37°C for 10 days. After this period, they were each inspected to determine the viability of the embryo and were examined for any abnormalities prior to the test. Subsequently, 300 µL of the test solutions and the vehicle control, that is, 0.9% saline, was pipetted onto the chorioallantoic membrane of the hen's egg (n=6 for each group). Irritation potential was classified by a scheme which depended on two components. The first was the calculated irritation score (IS). The IS was based on the time until adverse reactions (haemorrhage, vessel lysis and coagulation) were first observed. In this experiment, the eggs were observed continuously for 5 min for the appearance of lysis (L), haemorrhage (H) and/or coagulation (C) to determine the IS using the formula given below. The time for each reaction to occur was recorded in seconds (sec) and the degree of severity of each reaction (L, H, C) was graded as 0=no reaction, 1=slight reaction, 2=moderate reaction and 3=severe reaction.

$$IS = \frac{\{(301 - \text{secH})\} * 5}{300} + \frac{\{(301 - \text{secL})\} * 7}{300} + \frac{\{(301 - \text{secC})\} * 9}{300}$$

The second component of irritation potential was a determination of the severity (slight, moderate or severe) of adverse reactions after 1 and 5 min. The irritation threshold (TH) was defined as the lowest concentration at which slight reactions occur.

Statistical analysis

Data were reported as means±SD and analysed with using SPSS software, V.24.0. The data between groups were evaluated for statistical significance using Student's t-test and results were reported as p values, where p <0.05 were considered statistically significant.

RESULTS

2% T4O formulation exerts a broad-spectrum antimicrobial effects on USP <51> microorganisms

Although the control and the 2% T4O formulation were evaluated separately by 12 months, the same procedures were followed without deviation; therefore, the two results are comparable. The control with no T4O did not exert any inhibitory effects on these microorganisms, while the CFU/mL was <100 for *E. coli*, *C. albicans*, *P. aeruginosa*, *S. aureus* and 1.0×10^3 CFU/mL for *A. brasiliensis* after exposure to 2% T4O for 14 days (table 1). Their corresponding log reduction at day 14 were >3.6, >3.6, >3.4, >3.1 and 2.6, respectively, indicating that 2% T4O formulation was effective in killing these microorganisms. At day 28, the CFU/mL of all species including *A. brasiliensis* was <100, confirming that there was no growth increase from day 14 to 28. Collectively, these data indicated that 2% T4O formulation was effective in killing followed by inhibiting the microbial growth. Consequently, these results also support the notion that 2% T4O alone could establish and maintain sterility of this foam formulation so that no additional preservatives were required to be used. This finding has direct clinical importance, for example, to avoid preservative-induced ocular toxicity.

Previous reports have tested the antimicrobial effect of T4O in *Staphylococcus aureus*, methicillin-resistant *S. aureus* (MRSA), *P. aeruginosa*, *S. pneumoniae*, *Streptococcus epidermidis* and CoNS such as *S. capitis*.³⁵⁻⁴⁰ We thus expanded this analysis and evaluated whether formulation with 2% T4O was effective in exerting

Table 1 USP <51> antimicrobial effectiveness test result

Test organisms	ATCC#	Initial concentration (CFU/mL)	Time point			
			14 day		28 day	
			CFU/mL	Log reduction	CFU/mL	Log reduction
<i>Escherichia coli</i>	8739	3.7×10^5	<100	>3.6	<100	>3.6
<i>Pseudomonas aeruginosa</i>	9027	2.3×10^5	<100	>3.4	<100	>3.4
<i>Staphylococcus aureus</i>	6538	1.4×10^5	<100	>3.1	<100	>3.1
<i>Candida albicans</i>	10231	4.1×10^5	<100	>3.6	<100	>3.6
<i>Aspergillus brasiliensis</i>	16404	3.9×10^5	1.0×10^3	2.6	<100	>3.6

2% T4O formulation exerts a broad-spectrum antimicrobial effect on microorganisms related to common eye diseases within 60 s. ATCC, American Type Culture Collection; CFU, colony-forming unit; USP, United States Pharmacopeia.

Table 2 Rapid time kill test result

Microorganism	ATCC#	Control	Post 60s exposure to 2% T4O	Log10 reduction	Reduction (%)
		Avg. CFU/mL	Avg. CFU/mL		
<i>Acinetobacter baumannii</i>	19606	9.5×10 ⁶	0	6.98	>99.99
<i>Clostridium prefringens</i>	13124	5.5×10 ⁶	0	6.72	
<i>Haemophilus influenza</i>	49144	3.4×10 ⁶	0	6.53	
<i>Morexella catarrhalis</i>	8176	5.1×10 ⁶	0	6.71	
<i>Propionibacterium acne</i>	6919	1.34×10 ⁶	0	6.13	
<i>Klebsiella pneumonia</i>	10031	5.5×10 ⁶	9.0×10 ¹	4.79	
<i>Bacteriodes fragilis</i>	25285	4.5×10 ⁶	3.1×10 ²	4.16	
<i>Enterobacter aerogenes</i>	51697	1.10×10 ⁶	6.5×10 ²	3.23	>96–99
<i>Streptococcus pyogenes</i>	49399	6.3×10 ⁶	5.6×10 ⁶	2.05	
<i>Proteus mirabilis</i>	14153	2.33×10 ⁸	3.65×10 ⁶	1.81	
<i>Streptococcus saprophyticus</i>	35552	1.49×10 ⁶	5.0×10 ⁴	1.47	
<i>Acanthamoeba castellanii</i>	30011	4.1×10 ⁶	7.8×10 ⁴	1.72	
<i>Serratia marcescens</i>	14756	1.97×10 ⁶	1.56×10 ⁵	1.09	>91
<i>Enterococcus faecium</i>	51559	7.55×10 ⁷	6.35×10 ⁶	1.08	
<i>Staphylococcus hominis</i>	27844	1.37×10 ⁷	5.75×10 ⁶	0.37	58
<i>Trichophyton interdigitalewas</i>	9533	2.25×10 ⁷	1.35×10 ⁷	0.22	40
<i>Staphylococcus haemolyticus</i>	29970	2.60×10 ⁶	1.84×10 ⁶	0.15	29
<i>Aspergillus brasiliensis</i>	16404	1.8×10 ⁵	2.0×10 ⁵	-0.05	0

2% T4O is safe and does not cause skin and eye irritation.

ATCC, American Type Culture Collection; CFU, colony-forming unit.

an antimicrobial effect against other microorganisms related to ocular/skin infections (as listed in table 2) including 15 bacterial species (8 Gram-negative, 7 Gram-positive), 2 fungi (*Trichophyton interdigitale* and *A. brasiliensis*) and *Acanthamoeba castellanii*. Within 60 s of exposure to 2% T4O formulation, *Acinetobacter baumannii*, *Clostridium prefringens*, *Haemophilus influenza*, *Morexella catarrhalis* and *Propionibacterium acne* were killed entirely (CFU/mL=0). Moreover, *Klebsiella pneumonia* and *Bacteriodes fragilis* were killed by >99.99%, *Enterobacter aerogenes*, *Streptococcus pyogenes*, *Proteus mirabilis* and *Streptococcus saprophyticus* were killed by 96%–99%, *Serratia marcescens* and *Enterococcus faecium* were killed ~92%, while *S. hominis*, *Trichophyton interdigitalewas* and *St. haemolyticus* were killed at ~58%, ~40% and ~29%, respectively. Although 2% T4O did not exert an effective killing effect against *A. brasiliensis*, within a short exposure time of 60 s, the USP <51> test results indicated that a longer exposure time was effective in eradicating *A. brasiliensis*. Additionally, 2% T4O uniquely exerted a potent killing effect against *A. castellanii* (98.1%) which is commonly responsible for difficult to treat cases of infectious keratitis. Collectively, these data support the notion that 2% T4O formulation exerts a broad-spectrum

killing effect against a number of microorganisms found in common eye diseases.

A total of 58 subjects (13 men and 45 women, age range: 18–78 years) were subjected to the RIPT with 2% T4O. Of them, 55 subjects satisfactorily completed the test procedures while three subjects discontinued for personal reasons unrelated to the study. After exposure to 2% T4O, there was no evidence of irritation, allergy, sensitisation or any other skin reactivity observed or reported by any of these 55 subjects at any time during or on completion of both induction and challenge study. The IS was 0.0 for all 55 subjects, indicating that 2% T4O did not cause any skin irritation in human volunteers.

The ocular irritation was evaluated by the HET-CAM test. The results showed the appearance of lysis and haemorrhage in the positive controls, that is, 1% (w/v) SDS and 0.1N NaOH, and the appearance of coagulation in the 0.1N NaOH positive control. The mean calculated IS was 10.4±0.17 for 1% SDS and 16.8±0.18 for 0.1n NaOH. In contrast, the score for 2% T4O was 0.0 and threshold concentration was found to be >10%, which was the same as the vehicle control, that is, 0.9% saline. These data show that the irritation potential of 2% T4O is comparable to 0.9% saline and significantly <1% SDS (p<0.001) and 0.1N NaOH (p<0.001).

DISCUSSION

Effective ocular hygiene will not only reduce microbial colonisation in the skin and lid margin but also prevent spreading microbes to the ocular surface causing conjunctivitis, keratitis and even sight-threatening endophthalmitis. In this regard, the foam formulation of 2% T4O can be an effective and viable option to achieve this objective as it demonstrated cidal activity against all microorganisms listed in USP <51> at both 14 and 28 days and exerted a rapid killing effect within 60s against a number of Gram-positive and Gram-negative ocular isolates, such as *A. baumannii* that causes endophthalmitis infection,⁴¹ *Moraxella* that causes conjunctivitis and keratitis,⁴² and *Propionibacterium acne* that causes chronic blepharitis, endophthalmitis,^{43 44} Meibomian gland dysfunction (MGD) and dry eye.⁴⁵ T4O's potent antimicrobial effect, as shown in our study, is consistent with prior studies that show its effect against other common ocular isolates including *S. aureus*, *P. aeruginosa*, *S. pneumoniae* and CoNS^{11 36}; hence, they were not tested in our current study. Twenty-eight CoNS isolates including, *S. capitis* and *S. lugdunensis* have been previously shown to be killed by both 5% TTO and T4O.³⁷ We thus expanded our analysis to test the effectiveness of 2% T4O against additional microorganisms including *S. hominis* and *S. haemolyticus* where their CFU/mL were reduced by 58% and 29%, respectively within 60s. Lastly and most importantly, our data demonstrated that *A. castellanii* which is one of the most common causes of contact lens-related infectious keratitis⁴⁶ can be killed by 2% T4O. These results, together with our recent report that T4O is also effective in killing *Demodex* mites^{14 47} suggesting 2% T4O has a broad antimicrobial spectrum against eyelid-associated bacteria, fungi, amoeba and parasites. In addition, while we understand future studies will be needed to further determine antimicrobial resistance for those surviving microbes, 2% T4O does also achieved killing >99% of all microorganisms listed in USP <51> indicating that such a foam formulation does not require the addition of other preservatives such as benzalkonium chloride which has been shown to potentially cause ocular surface toxicity.^{48 49} On the contrary, although clinical efficacy of 2% T4O in treating ocular disease was not directly studied and the formulation was not directly tested on eyelid skin and the eyelid margin, 2% T4O formulation does exert antimicrobial activity against various microbes and it is unlikely to cause skin or ocular irritation as demonstrated by RIPT and Het-Cam test. These benefits are similar to the other researchers' finding that T4O also exerts anti-inflammatory actions by selectively regulating cell function, in particular monocyte activity,⁵⁰ and downregulating immune responses to foreign antigens in the skin.⁵¹ Collectively, we believe a foam formulation with 2% T4O can be used as an effective measure for ocular hygiene against potential microbial colonisation.

Contributors C-WS planned the study, analysed the data to draft manuscript and submitted the study. ST assisted in data analysis and manuscript drafting. HS and AMSC conducted manuscript review. SCGT oversaw the entire study, provided guidance and conducted final manuscript review.

Funding This work is supported by grants from National Institutes of Health, National Eye Institute, Bethesda, MD R43EY019586 (to SCGT), and TissueTech, Inc. and Ocular Surface Center, Miami, FL (contract grant sponsor).

Competing interests SCGT is an inventor, shareholder and employee of TissueTech, Inc. He has filed two patents for the use of tea tree oil and its ingredients for treating demodocosis. No other authors have any proprietary interest in any material in this study.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Lemp MA. Advances in understanding and managing dry eye disease. *Am J Ophthalmol* 2008;146:350–6.
- Spyridon S, Marinopoulos S. Blepharitis MBA. *Johns Hopkins Antibiotic (ABX) Guides*, 2014.
- Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. *Br J Ophthalmol* 1984;68:524–8.
- Dadaci Z, Kılınc F, Ozer TT, et al. Periodic acid-Schiff staining demonstrates fungi in chronic anterior blepharitis. *Eye* 2015;29:1522–7.
- Willcox MD. Characterization of the normal microbiota of the ocular surface. *Exp Eye Res* 2013;117:99–105.
- Jackson WB. Blepharitis: current strategies for diagnosis and management. *Can J Ophthalmol* 2008;43:170–9.
- John T, Shah AA. Use of azithromycin ophthalmic solution in the treatment of chronic mixed anterior blepharitis. *Ann Ophthalmol* 2008;40:68–74.
- Mandapati JS, Metta AK. Intraocular pressure variation in patients on long-term corticosteroids. *Indian Dermatol Online J* 2011;2:67–9.
- Hueso Abancens JR, Mengual Verdú E, Schargel Palacios K, et al. [Modification of the conjunctival flora with cleaning palpebral solutions]. *Arch Soc Esp Oftalmol* 2004;79:617–21.
- Morcía C, Malnati M, Terzi V. In vitro antifungal activity of terpinen-4-ol, eugenol, carvone, 1,8-cineole (eucalyptol) and thymol against mycotoxigenic plant pathogens. *Food Addit Contam Part A Chem Anal Control Expo Risk Assess* 2012;29:415–22.
- Cox SD, Mann CM, Markham JL. Interactions between components of the essential oil of *Melaleuca alternifolia*. *J Appl Microbiol* 2001;91:492–7.
- Hammer KA, Carson CF, Riley TV. Antifungal activity of the components of *Melaleuca alternifolia* (tea tree) oil. *J Appl Microbiol* 2003;95:853–60.
- Carson CF, Riley TV. Antimicrobial activity of the major components of the essential oil of *Melaleuca alternifolia*. *J Appl Bacteriol* 1995;78:264–9.
- Tighe S, Gao YY, Tseng SC. Terpinen-4-ol is the most active ingredient of tea tree oil to kill *demodex* mites. *Transl Vis Sci Technol* 2013;2:2: 2.
- English FP, Nutting WB. Demodicosis of ophthalmic concern. *Am J Ophthalmol* 1981;91:362–72.
- Gao YY, Di Pascuale MA, Elizondo A, et al. Clinical treatment of ocular demodocosis by lid scrub with tea tree oil. *Cornea* 2007;26:136–43.
- Cheng AM, Sheha H, Tseng SC. Recent advances on ocular demodex infestation. *Curr Opin Ophthalmol* 2015;26:295–300.
- Gao YY, Di Pascuale MA, Li W, et al. High prevalence of demodex in eyelashes with cylindrical dandruff. *Invest Ophthalmol Vis Sci* 2005;46:3089–94.
- Kheirkhah A, Casas V, Li W, et al. Corneal manifestations of ocular demodex infestation. *Am J Ophthalmol* 2007;143:743–9.

20. Lacey N, Delaney S, Kavanagh K, *et al.* Mite-related bacterial antigens stimulate inflammatory cells in rosacea1. *BrJ Dermatol* 2007;157:474–81.
21. Li J, O'Reilly N, Sheha H, *et al.* Correlation between ocular Demodex infestation and serum immunoreactivity to Bacillus proteins in patients with Facial rosacea. *Ophthalmology* 2010;117:870–7.
22. O'Reilly N, Menezes N, Kavanagh K. Positive correlation between serum immuno-reactivity to Demodex-associated Bacillus proteins and Erythematotelangiectic Rosacea. *BrJ Dermatol* 2012.
23. Hart PH, Brand C, Carson CF, *et al.* Terpinen-4-ol, the main component of the essential oil of *Melaleuca alternifolia* (tea tree oil), suppresses inflammatory mediator production by activated human monocytes. *Inflammation Research* 2000;49:619–26.
24. Pharmacopeia US. USP<51> Antimicrobial effectiveness testing.
25. Ra D, Block S, ed. *Principles of antimicrobial activity and resistance, disinfection, sterilization, and preservation*. 5th Edn. Philadelphia: Lea & Febiger, 2001.
26. Standard guide for assessment of antimicrobial activity using a time-kill procedure.
27. Saida H, Ytow N, Seki H. Photometric application of the gram stain method to characterize natural bacterial populations in aquatic environments. *Appl Environ Microbiol* 1998;64:742–7.
28. Desai MJ, Armstrong DW, Separation ADW. Separation, identification, and characterization of microorganisms by capillary electrophoresis. *Microbiol Mol Biol Rev* 2003;67:38–51.
29. Marzulli FN, Maibach HI. Contact allergy: predictive testing in man. *Contact Dermatitis* 1976;2:1–17.
30. ICCVAM-Recommended Test Method Protocol: Hen's Egg Test – Chorioallantoic Membrane (HET-CAM) Test Method.
31. Tavaszi J, Budai P. The use of HET-CAM test in detecting the ocular irritation. *Commun Agric Appl Biol Sci* 2007;72:137–41.
32. Steiling W, Bracher M, Courtellemont P, *et al.* The HET-CAM, a Useful In Vitro Assay for Assessing the Eye Irritation Properties of Cosmetic Formulations and Ingredients. *Toxicol In Vitro* 1999;13:375–84.
33. Spielmann H, Gerner I, Kalweit S, *et al.* Interlaboratory assessment of alternatives to the Draize eye irritation test in Germany. *Toxicol In Vitro* 1991;5:539–42.
34. Gilleron L, Coecke S, Sysmans M, *et al.* Evaluation of a modified HET-CAM assay as a screening test for eye irritancy. *Toxicol In Vitro* 1996;10:431–46.
35. Bol KA, Collins JS, Kirby RS. Survival of infants with neural tube defects in the presence of folic acid fortification. *Pediatrics* 2006;117:803–13.
36. Ferrini AM, Mannoni V, Aureli P, *et al.* *Melaleuca alternifolia* essential oil possesses potent anti-staphylococcal activity extended to strains resistant to antibiotics. *Int J Immunopathol Pharmacol* 2006;19:539–44.
37. Loughlin R, Gilmore BF, McCarron PA, *et al.* Comparison of the cidal activity of tea tree oil and terpinen-4-ol against clinical bacterial skin isolates and human fibroblast cells. *Lett Appl Microbiol* 2008;46:428–33.
38. Christoph F, Kaulfers PM, Stahl-Biskup E. A comparative study of the in vitro antimicrobial activity of tea tree oils s.l. with special reference to the activity of beta-triketones. *Planta Med* 2000;66:556–60.
39. Inouye S, Takizawa T, Yamaguchi H. Antibacterial activity of essential oils and their major constituents against respiratory tract pathogens by gaseous contact. *J Antimicrob Chemother* 2001;47:565–73.
40. Hammer KA, Carson CF, Riley TV. Susceptibility of transient and commensal skin flora to the essential oil of *Melaleuca alternifolia* (tea tree oil). *Am J Infect Control* 1996;24:186–9.
41. Chen KJ, Hou CH, Sun MH, *et al.* Endophthalmitis caused by *Acinetobacter baumannii*: report of two cases. *J Clin Microbiol* 2008;46:1148–50.
42. Whitcher JP, Cevallos V, Moraxella CV. Moraxella, down but not out—the eye bug that won't go away. *Br J Ophthalmol* 2006;90:1215–6.
43. Dougherty JM, McCulley JP. Analysis of the free fatty acid component of meibomian secretions in chronic blepharitis. *Invest Ophthalmol Vis Sci* 1986;27:52–6.
44. Dougherty JM, McCulley JP. Bacterial lipases and chronic blepharitis. *Invest Ophthalmol Vis Sci* 1986;27:486–91.
45. Narayanan S, Redfern RL, Miller WL, *et al.* Dry eye disease and microbial keratitis: is there a connection? *Ocul Surf* 2013;11:75–92.
46. Lorenzo-Morales J, Khan NA, Walochnik J. An update on *Acanthamoeba keratitis*: diagnosis, pathogenesis and treatment. *Parasite* 2015;22:10.
47. Cw S, S T. Microorganisms and Common Ophthalmic Diseases. *Int J Ophthalmol Eye Sci* 2017;5:272–6.
48. Ammar DA, Noecker RJ, Kahoook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. *Adv Ther* 2010;27:837–45.
49. Chen W, Li Z, Hu J, *et al.* Corneal alternations induced by topical application of benzalkonium chloride in rabbit. *PLoS One* 2011;6:e26103.
50. Brand C, Ferrante A, Prager RH, *et al.* The water-soluble components of the essential oil of *Melaleuca alternifolia* (tea tree oil) suppress the production of superoxide by human monocytes, but not neutrophils, activated in vitro. *Inflammation Research* 2001;50:213–9.
51. Nogueira MN, Aquino SG, Rossa Junior C, *et al.* Terpinen-4-ol and alpha-terpineol (tea tree oil components) inhibit the production of IL-1 β , IL-6 and IL-10 on human macrophages. *Inflamm Res* 2014;63:769–78.